Meningeal SMARCB1 ‐deficient tumors: an emerging group of meningeal tumors

ConclusionsThe phenotype and genotype of these two cases did not fit diagnostically with entities already known to be SMARCB1‐deficient tumors. As both tumors shared common features, they are regarded as belonging to an emerging group of primary meningeal SMARCB1‐deficient tumors, not described to date. In order to facilitate the identification and characterization of these tumors, we recommend SMARCB1 immunohistochemistry for primary meningeal tumors which are difficult to classify, especially if immunopositive for EMA and CD34.This article is protected by copyright. All rights reserved.

Source: Neuropathology and Applied Neurobiology - September 30, 2016 Category: Neurology Authors: B érengère Dadone, Denys Fontaine, Lydiane Mondot, Gaël Cristofari, Anne Jouvet, Catherine Godfraind, Pascale Varlet, Dominique Ranchère‐Vince, Jean‐Michel Coindre, Lauris Gastaud, Christian Baudoin, Annie‐Claude Peyron, Antoine Thyss, Michael C Tags: Original Article Source Type: research